Previous 10 | Next 10 |
Anaplan (NYSE: PLAN ) -29% despite Q4 beat . More news on: Anaplan, Inc., Continental Resources, Inc., Nutanix, Inc., Stocks on the move, , Read more ...
Amarin (NASDAQ:AMRN) released better-than-expected 2019 fourth-quarter results after the closing bell Tuesday. The biopharma's stock promptly dropped by another 0.86%, bringing its total loss for the year to a disappointing 18.4%. What's behind this relentless downward trend? Well, fi...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Will the global equity selloff extend for another day? That's the question traders are asking this morning as U.S. futures hovered...
Image source: The Motley Fool. Amarin Corporation plc (NASDAQ: AMRN) Q4 2019 Earnings Call Feb 25, 2020 , 4:30 p.m. ET Operator Continue reading
Amarin Corporation plc (AMRN) Q4 2019 Results Earnings Conference Call February 25, 2020 04:30 PM ET Company Participants Elisabeth Schwartz - Senior Director of Investor Relations John Thero - President and Chief Executive Officer Mike Kalb - Chief Financial Officer Aaron Berg...
Amarin (NASDAQ: AMRN) announced its fourth-quarter and full-year financial results on Tuesday afternoon. The company managed to beat both the revenue and earnings targets set by Wall Street analysts, thanks in no small part to sales of its fish-oil derived drug, Vascepa. The pharmaceutical...
Amarin (NASDAQ: AMRN ) reports Q4 beats with 85% Y/Y revenue growth. More news on: Amarin Corporation plc, Healthcare stocks news, Earnings news and commentary, Read more ...
Amarin (NASDAQ: AMRN ): Q4 Non-GAAP EPS of $0.04 beats by $0.06 ; GAAP EPS of $0.02 beats by $0.04 . Revenue of $143.3M (+85.3% Y/Y) beats by $5.6M . Shares +1.7% . Press Release More news on: Amarin Corporation plc, Earnings news and commentary, Stocks on the move, Healthcare ...
Record Revenue of $429.8 Million and $143.3 Million for Full Year and Fourth Quarter 2019 Launch Commenced of VASCEPA ® as First and Only Drug with Its New Cardiovascular Risk Reduction Indication Management to Host Conference Call at 4:30 p.m. ET Today DUB...
Esperion Gets FDA Nod for Nexletol Esperion Therapeutics (ESPR) reported that its lead drug candidate Nexletol has been approved by the FDA for lowering LDL-C in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. The treatment has ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...